VB-001
Acute Ischemic Stroke
Key Facts
About VST Bio
VST Bio is a preclinical-stage biotech translating Yale-discovered technologies into novel antibody therapies for diseases driven by vascular leak, such as stroke, ARDS, and sepsis. Its lead candidate, VB-001, is a dual-acting antibody designed to normalize vascular integrity and reduce inflammation, aiming to dramatically limit tissue damage. The company plans to initiate clinical trials in 2026, targeting a significant unmet need in stroke where most patients are ineligible for current standard-of-care therapies.
View full company profileAbout VST Bio
VST Bio is a preclinical-stage biotech translating Yale-discovered technologies into novel antibody therapies for diseases driven by vascular leak, such as stroke, ARDS, and sepsis. Its lead candidate, VB-001, is a dual-acting antibody designed to normalize vascular integrity and reduce inflammation, aiming to dramatically limit tissue damage. The company plans to initiate clinical trials in 2026, targeting a significant unmet need in stroke where most patients are ineligible for current standard-of-care therapies.
View full company profileAbout VST Bio
VST Bio is a preclinical-stage biotech translating Yale-discovered technologies into novel antibody therapies for diseases driven by vascular leak, such as stroke, ARDS, and sepsis. Its lead candidate, VB-001, is a dual-acting antibody designed to normalize vascular integrity and reduce inflammation, aiming to dramatically limit tissue damage. The company plans to initiate clinical trials in 2026, targeting a significant unmet need in stroke where most patients are ineligible for current standard-of-care therapies.
View full company profileTherapeutic Areas
Other Acute Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| Presendin™ (Exenatide) | Invex Therapeutics | Phase 2 |
| Supernova Stent Retriever | Gravity Medical Technology | Commercial |
| Neutron Reperfusion Catheter | Gravity Medical Technology | Commercial |
| AST-004 | Astrocyte Pharmaceuticals | Phase 1/2 |
| scp776 | Silver Creek Pharmaceuticals | Phase 2 |
| Pulse NanoMED for AIS | Euphrates Vascular | Pre-clinical |
| NeVa NET | Vesalio | Development/Commercial |
| ApTOLL | aptaTargets | Phase 2 |
| ThermoSuit® for Acute Ischemic Stroke | Life Recovery Systems HD | Pivotal Trial (Planned) |
| Pulsante for Ischemic Stroke | Realeve | Research/Clinical Study |
| Glenzocimab (ACT017) | Acticor Biotech | Phase 2/3 |
| eTrieve™ Microcatheter | Magneto Thrombectomy Solutions | Phase 1 |